The Functional Living Index-Cancer (FLIC) was administered to 438 patients in the Lung Cancer Study Group on whom long-term follow-up was available in 1993. Across all trials, the total FLIC score was predictive for survival even when corrected for extent of disease, although individual items on the FLIC were not. There was no significant impact of a short course of chemotherapy on quality of life. The FLIC is a reliable means of assessing quality of life in lung cancer surgical adjuvant trials.
The conceptual roots of quality-of-life (QOL) assessment arose in a social and political context that sought to evaluate the impact of various economic and educational interventions on the broader scope of human existence. 1 3 As applied to medicine, and particularly to oncology, these measures seek to balance the competing effects of the disease and its therapy on the physical and psychological well-being of the individual patient. The QOL assessment has been emphasized in oncologic care only since the advent of systemic chemotherapy.3 There was little questioning of the value of potentially curative surgery or radiation and the physical impact of palliative radiation therapy on the patient was trivial compared with the relief of symptoms usually afforded. Chemotherapy, however, caused an enormous array of side effects and its widespread introduction through the 1970s led many practitioners to conclude that the quality of a patient's survival was not enhanced by the addition of chemotherapy. Although QOL assessment was often employed as an excuse for a policy of "no active treatment," the focus on QOL has led to a better understanding of the competing risks and benefits of a particular therapy.
This conflict has been nowhere more relevant than in the context of non-small cell lung cancer (NSCLC), an illness that is fatal to more than 85% of those who contract it. 4 creasing the intensity of therapy. The nurse data-managers of the LCSG first raised these issues in the context of the group's studies and LCSG 85Q was designed to address this trade-off between quality and quantity of survival. As such, it was initially conceived of as a longitudinal study of the impact of chemotherapy on patients who had possibly been cured by surgery alone.
In 1989 and 1991, we reported the initial findings in 437 patients treated on eight different LCSG trials and noted little or no impact of a short course of chemotherapy on QOL over time.10 Most surprising to us was the ability of the QOL score alone to predict for recurrence and survival even when corrected for stage, treatment, and performance status,10 a finding now duplicated by three other groups."1 13 With the loss of funding for the group in 1989, there was a halt to further QOL data collection, but survival continued to be assessed. In 1993, funds were identified to update the clinical outcome files and reanalyze the QOL results. Long-term follow-up, including survival, was available on 438 patients. Our interest in further exploring the connection of QOL results to survival led us to focus on this group of patients.
METHODS
The instrument chosen to assess QOL was the Functional Living Index-Cancer (FLIC) developed by Schipper and his colleagues'4 in Manitoba. It was applied to all LCSG trials currently active in 1985. Because it was initiated during the course of several trials, the number of patients from each trial varies. The purpose of each individual trial, the outcome of that trial, and the number of patients entered on 85Q from that protocol are given in Table 1."5 All patients had the FLIC administered prior to any studybased therapy. This has different meanings for each trial. The patients placed on the postoperative adjuvant studies (LCSG 801, 853) had already completed surgery before randomization, whereas the FLIC was administered before any therapy in the other trials. Follow-up assessments varied in their intervals but all were done just prior to a treatment. Control patients had monthly or quarterly assessments to match their clinical follow-up. Patients were assisted with understanding the instrument but the staff did not fill it in for them. French and Spanish translations appropriate to the French-Canadian and Mexican-American populations at several of our centers were implemented. Scoring was done by the nurse-data manager, recording both the individual item scores and the "total' score, all of which were entered on computer.
Statistical Analysis
The initial objective of the study was to assess the impact of therapy on QOL over time. There were two additional objectives: the prognostic impact of baseline QOL on recurrence and survival, and the impact of individual items or factors from the FLIC on prognosis.
All event times were measured from the date of registration or randomization onto LCSG studies. Event time distributions were estimated using the product limit method.'6 The significance of prognostic factors on event times was estimated using relative risk regression models. For baseline prognostic factors, the proportional hazards regression model was used.17 To control for the effect of more than one prognostic factor simultaneously, multiple regression models were used. An important feature of the design of this QOL study was the collection of longitudinal QOL assessments. The prognostic significance of longitudinal QOL features, the baseline QOL score was the strongest preTo meet the item/factor objective, a principal component dictive factor for survival and independent of Karnofsky factor analysis was performed.19 An oblique factor rotation was performance status (Table 3 ). The initial QOL score and used in an attempt to obtain clinically meaningful factors. Fac- the change in QOL score over time (modeled linearly) tors were then tested for prognostic significance using the method oulie abve were significantly prognostic for survival (Table 3) .
Two trials (801 and 853) directly compared chemotherapy following surgery to surgery alone; neither trial dem-RESULTS onstrated a positive impact on survival.202' Initial QOL Follow-up was obtained, where possible, through Sep- scores did not differ between the two arms of each trial nor tember 1993 for 438 patients. Univariate proportional was there any difference in QOL score over time (Table 4 ). hazards models for recurrence and survival demonstrated
The impact of QOL score on survival across all studies is significant predictive value for the total QOL score, Kargraphically demonstrated in Figure 1 . nofsky performance status, weight loss, and several stageThe impact of individual items from the FLIC was surand disease-related factors (Table 2) . A multivariate proveyed for their impact on survival (Table 4) . Although the portional hazards model was developed for survival and univariate analysis shown in Table 5 suggests an impact of again demonstrated a significant impact of QOL, T status, questions relating to the disruption of current life-style N status, performance status, and small cell histologic fea-(ability to do regular tasks, appearance), the patient's comfort, and the impact of the cancer on those closest to them, these disappeared when stage was considered in the stratified proportional hazards model (omitting total score). Consequently, despite the impact of the total QOL score, no individual items were significantly prognostic for survival ( Table 5 ).
The results of the principal component factor analysis with Promax rotation is shown in Table 6 . Using this oblique factor rotation method, the factors are not completely independent (Table 7) , but all pair-wise factor correlations were below 0.4. Although factor interpretation is ultimately subjective, we believe that reasonable generalizations can be made concerning each of the five factors (Table 8). These five factors account for 60% of the variability in QOL scores. All correlations of the factor structure with survival disappeared when corrected for stage of disease.
DISCUSSION
This trial demonstrates a number of important points with respect to QOL trials in lung cancer. First, despite difficulties experienced in other cooperative group settings,22 The LCSG was able to administer and score the instrument over a broad range of trials. It required significant effort, however, and was not adequately reimbursed by the treatment-related funding mechanism in place in 1985 through 1989. Absent an independent commitment to the trial from the nurse-data managers, it would not have been completed. There is ongoing discussion about which instrument is superior for measuring QOL, with several instruments proposed as useful for lung cancer trials.10"12"13-39 The psychometric properties of the FLIC were initially developed on a population of patients with breast cancer,14 but the similarities in the factor analysis suggest similar reliability in a lung cancer population.
This update of LCSG 85Q shows that there is no significant change in QOL during adjuvant therapy for NSCLC. This finding may reflect the improvement in antiemetic efficacy seen in the late 1980s, even before the advent of the serotonin-antagonist antiemetics, or it may reflect the generally excellent performance status of patients with resected lung cancer. In either case, there would appear to be no QOL contraindication to such therapy. Whether this will change with combined-modality therapy, as is being tested in the current Intergroup Adjuvant Trial, or with more intense chemotherapy will require further study.
What remains intriguing is the prognostic significance of the total QOL score. It is clear that no single item or factor is skewing the total score and, in fact, none is prognos- Table 5 for explanation of partial words. Table 5 .
